Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease

Background: Patients with inflammatory bowel disease (IBD) are at an increased risk of developing Clostridioides difficile infection (CDI). Treatment of CDI in patients with IBD is challenging due to higher failure rates and concomitant IBD activity. Objectives: We performed a multicentre cohort stu...

Full description

Bibliographic Details
Main Authors: Emilie (E.) van Lingen, Simon (S. M. D.) Baunwall, Simone (S. C.) Lieberknecht, Nicolas (N.) Benech, Gianluca (G.) Ianiro, Harry (H.) Sokol, Alessandro (A.) Gasbarrini, Giovanni (G.) Cammarota, Marcel (M. K.) Eriksen, Andrea (A. E.) van der Meulen-de Jong, Elizabeth (E. M.) Terveer, Hein (H. W.) Verspaget, Maria (M.) Vehreschild, Christian (C. L.) Hvas, Josbert (J. J.) Keller
Format: Article
Language:English
Published: SAGE Publishing 2023-03-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848231156285
_version_ 1811158095053717504
author Emilie (E.) van Lingen
Simon (S. M. D.) Baunwall
Simone (S. C.) Lieberknecht
Nicolas (N.) Benech
Gianluca (G.) Ianiro
Harry (H.) Sokol
Alessandro (A.) Gasbarrini
Giovanni (G.) Cammarota
Marcel (M. K.) Eriksen
Andrea (A. E.) van der Meulen-de Jong
Elizabeth (E. M.) Terveer
Hein (H. W.) Verspaget
Maria (M.) Vehreschild
Christian (C. L.) Hvas
Josbert (J. J.) Keller
author_facet Emilie (E.) van Lingen
Simon (S. M. D.) Baunwall
Simone (S. C.) Lieberknecht
Nicolas (N.) Benech
Gianluca (G.) Ianiro
Harry (H.) Sokol
Alessandro (A.) Gasbarrini
Giovanni (G.) Cammarota
Marcel (M. K.) Eriksen
Andrea (A. E.) van der Meulen-de Jong
Elizabeth (E. M.) Terveer
Hein (H. W.) Verspaget
Maria (M.) Vehreschild
Christian (C. L.) Hvas
Josbert (J. J.) Keller
author_sort Emilie (E.) van Lingen
collection DOAJ
description Background: Patients with inflammatory bowel disease (IBD) are at an increased risk of developing Clostridioides difficile infection (CDI). Treatment of CDI in patients with IBD is challenging due to higher failure rates and concomitant IBD activity. Objectives: We performed a multicentre cohort study in patients with IBD who received fecal microbiota transplantation (FMT) for recurrent CDI (rCDI), to further investigate factors that influence the clinical outcome and course of both rCDI and IBD. Design: This is a multicentre cohort study conducted in five European FMT centres. Methods: Adult IBD patients treated with FMT for rCDI were studied. Cure was defined as clinical resolution of diarrhoea or diarrhoea with a negative C. difficile test. The definition of an IBD flare was record based. Long-term follow-up data were collected including new episodes of CDI, IBD flares, infections, hospital admissions, and death. Results: In total, 113 IBD patients underwent FMT because of rCDI. Mean age of the patients was 48 years; 64% had ulcerative colitis. Concomitant rCDI was associated with an IBD flare in 54%, of whom 63% had received IBD remission-induction therapy prior to FMT. All FMT procedures were preceded by vancomycin treatment, 40% of patients received FMT via colonoscopy. CDI cure rate was 71%. Long-term follow-up data were available in 90 patients with a median follow-up of 784 days (402–1251). IBD activity decreased in 39% of patients who had active IBD at baseline, whereas an IBD flare occurred in only 5%. During follow-up of up to 2 years, 27% of the patients had infections, 39% were hospitalized, 5% underwent colectomy, and 10% died (median age of these latter patients: 72 years). Conclusion: FMT for rCDI in IBD patients is safe and effective, and IBD exacerbation after FMT is infrequent. Further studies should investigate the effects on IBD course following FMT.
first_indexed 2024-04-10T05:17:26Z
format Article
id doaj.art-d1e5885c4fe14d608dda3e4027daaf28
institution Directory Open Access Journal
issn 1756-2848
language English
last_indexed 2024-04-10T05:17:26Z
publishDate 2023-03-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Gastroenterology
spelling doaj.art-d1e5885c4fe14d608dda3e4027daaf282023-03-08T17:03:29ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482023-03-011610.1177/17562848231156285Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel diseaseEmilie (E.) van LingenSimon (S. M. D.) BaunwallSimone (S. C.) LieberknechtNicolas (N.) BenechGianluca (G.) IaniroHarry (H.) SokolAlessandro (A.) GasbarriniGiovanni (G.) CammarotaMarcel (M. K.) EriksenAndrea (A. E.) van der Meulen-de JongElizabeth (E. M.) TerveerHein (H. W.) VerspagetMaria (M.) VehreschildChristian (C. L.) HvasJosbert (J. J.) KellerBackground: Patients with inflammatory bowel disease (IBD) are at an increased risk of developing Clostridioides difficile infection (CDI). Treatment of CDI in patients with IBD is challenging due to higher failure rates and concomitant IBD activity. Objectives: We performed a multicentre cohort study in patients with IBD who received fecal microbiota transplantation (FMT) for recurrent CDI (rCDI), to further investigate factors that influence the clinical outcome and course of both rCDI and IBD. Design: This is a multicentre cohort study conducted in five European FMT centres. Methods: Adult IBD patients treated with FMT for rCDI were studied. Cure was defined as clinical resolution of diarrhoea or diarrhoea with a negative C. difficile test. The definition of an IBD flare was record based. Long-term follow-up data were collected including new episodes of CDI, IBD flares, infections, hospital admissions, and death. Results: In total, 113 IBD patients underwent FMT because of rCDI. Mean age of the patients was 48 years; 64% had ulcerative colitis. Concomitant rCDI was associated with an IBD flare in 54%, of whom 63% had received IBD remission-induction therapy prior to FMT. All FMT procedures were preceded by vancomycin treatment, 40% of patients received FMT via colonoscopy. CDI cure rate was 71%. Long-term follow-up data were available in 90 patients with a median follow-up of 784 days (402–1251). IBD activity decreased in 39% of patients who had active IBD at baseline, whereas an IBD flare occurred in only 5%. During follow-up of up to 2 years, 27% of the patients had infections, 39% were hospitalized, 5% underwent colectomy, and 10% died (median age of these latter patients: 72 years). Conclusion: FMT for rCDI in IBD patients is safe and effective, and IBD exacerbation after FMT is infrequent. Further studies should investigate the effects on IBD course following FMT.https://doi.org/10.1177/17562848231156285
spellingShingle Emilie (E.) van Lingen
Simon (S. M. D.) Baunwall
Simone (S. C.) Lieberknecht
Nicolas (N.) Benech
Gianluca (G.) Ianiro
Harry (H.) Sokol
Alessandro (A.) Gasbarrini
Giovanni (G.) Cammarota
Marcel (M. K.) Eriksen
Andrea (A. E.) van der Meulen-de Jong
Elizabeth (E. M.) Terveer
Hein (H. W.) Verspaget
Maria (M.) Vehreschild
Christian (C. L.) Hvas
Josbert (J. J.) Keller
Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease
Therapeutic Advances in Gastroenterology
title Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease
title_full Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease
title_fullStr Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease
title_full_unstemmed Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease
title_short Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease
title_sort short and long term follow up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease
url https://doi.org/10.1177/17562848231156285
work_keys_str_mv AT emilieevanlingen shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT simonsmdbaunwall shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT simonesclieberknecht shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT nicolasnbenech shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT gianlucagianiro shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT harryhsokol shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT alessandroagasbarrini shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT giovannigcammarota shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT marcelmkeriksen shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT andreaaevandermeulendejong shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT elizabethemterveer shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT heinhwverspaget shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT mariamvehreschild shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT christianclhvas shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease
AT josbertjjkeller shortandlongtermfollowupafterfecalmicrobiotatransplantationastreatmentforrecurrentinfectioninpatientswithinflammatoryboweldisease